
Ukko is an innovative biotechnology company focused on solving food allergies and sensitivities. Leveraging a computational protein design platform, they develop revolutionary therapeutics that aim to modulate the immune system without triggering allergic responses. Their approach involves creating a clinically validated map of the molecular structure of food allergies to understand biological mechanisms. Using AI and micro-engineering, they redesign allergens into safe and effective therapeutics. The company targets the significant social, health, and economic impact of rising food allergies, with the goal of improving the lives of millions affected.

Ukko is an innovative biotechnology company focused on solving food allergies and sensitivities. Leveraging a computational protein design platform, they develop revolutionary therapeutics that aim to modulate the immune system without triggering allergic responses. Their approach involves creating a clinically validated map of the molecular structure of food allergies to understand biological mechanisms. Using AI and micro-engineering, they redesign allergens into safe and effective therapeutics. The company targets the significant social, health, and economic impact of rising food allergies, with the goal of improving the lives of millions affected.
Sector: Biotechnology — therapeutics for food allergies
Founded: 2016
Headquarters: Rehovot, Israel
Tech: Computational protein design / AI-enabled protein micro‑engineering
Notable investors: Time Ventures (Marc Benioff), Continental Grain Company, Khosla Ventures, Leaps by Bayer
Food allergies and sensitivities, including gluten-related disorders
2016
Biotechnology
Latest round recorded as Series B on Jan 27, 2021 (per coverage).
“Includes Time Ventures (Marc Benioff), Continental Grain Company, Khosla Ventures, Leaps by Bayer, Israel Biotech Fund, Fall Line Capital, Innovation Endeavors, Marc Benioff, PeakBridge, Sanara Capital, Skyviews Life Science”